SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1733)11/30/2005 10:25:58 AM
From: rkrw  Respond to of 2355
 
OT, sorry to clog with vygr questions, but it's a competing phase III AD, so not terribly OT.

Has anyone heard of a case where the principal investigator is also the company's CSO? It is for voyager's memryte AD trial. I'm surprised this is allowed. Was wondering if anyone was aware of any precedent.



To: NeuroInvestment who wrote (1733)11/30/2005 10:37:23 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 2355
 
>> so anything is possible <<

Alzheimer's is a small part of the business plan. Yes, those at Myriad believe that it's a large part, but Meldrum is a little slow on the "hey, here's reality!" learning curve.

They're damn fast on the technology curve, however.

Thanks for the opinions, Harry. Believe that I was begging for them somewhere here, recently.

:-)

Rick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News